# The PEERLESS II Study

Study · id `cardio:ct-nct06055920` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06055920](<https://clinicaltrials.gov/study/NCT06055920>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06055920

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1200 participants.

## Technical summary

Registry record NCT06055920. Randomized; no masking; primary purpose treatment. Start 2023-11-17 (actual); primary completion 2026-07-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1200 participants (enrolled count; ClinicalTrials.gov record NCT06055920, source copy `cardio:ctgov-nct06055920-2026-11-03`, retrieved 2026-11-18)
- Started: 2023-11-17 (actual) (ClinicalTrials.gov record NCT06055920, source copy `cardio:ctgov-nct06055920-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2026-07-30 (actual) (ClinicalTrials.gov record NCT06055920, source copy `cardio:ctgov-nct06055920-2026-11-03`, retrieved 2026-11-18)
- Completion: 2026-10-30 (actual) (ClinicalTrials.gov record NCT06055920, source copy `cardio:ctgov-nct06055920-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Belgium; Canada; Denmark; France; Germany; Spain; Switzerland (ClinicalTrials.gov record NCT06055920, source copy `cardio:ctgov-nct06055920-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06055920-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: The PEERLESS II Study
- Condition: Pulmonary Embolism
- Intervention (Device): FlowTriever System
- Intervention (Drug): Anticoagulation Agents
- Lead sponsor: Inari Medical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Inari Medical (`cardio:org-inari-medical`)

## Provenance

Content hash: 1a2987056d7abb22af3d1585986157c4e3f8bc856f48881ea38644397cc8f144
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
